Wikipedia

Azficel-T

Azficel-T, sold under the brand name Laviv, is a cell therapy product for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.[1][2][3] It consists of fibroblasts harvested from the patient's own skin.[2]

Azficel-T
Clinical data
Trade namesLaviv
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration		Intradermal
ATC code
  • None
Legal status
Legal status
Identifiers
DrugBank
UNII

It was approved for medical use in the United States in June 2011.[2]

References

edit
  1. ^ a b "Laviv (Azficel-T)". U.S. Food and Drug Administration (FDA). 22 July 2017. Archived from the original on 16 December 2019. Retrieved 1 April 2020.
  2. ^ a b c d "Autologous Fibroblasts". U.S. Food and Drug Administration (FDA). 29 June 2017. Archived from the original on 22 July 2017. Retrieved 1 April 2020.{{cite web}}: CS1 maint: unfit URL (link)
  3. ^ "Laviv (azficel-T) Suspension for Intradermal Injection" (PDF). Food and Drug Administration. Archived from the original on 14 December 2019. Retrieved 2 April 2020.

Further reading

edit
  • Smith SR, Munavalli G, Weiss R, Maslowski JM, Hennegan KP, Novak JM (July 2012). "A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles". Dermatol Surg. 38 (7 Pt 2): 1234–43. doi:10.1111/j.1524-4725.2012.02349.x. PMID 22409385. S2CID 24901992.{{cite journal}}: CS1 maint: overridden setting (link)
edit
  • "Laviv (azficel-T)". Medscape. 28 September 2019.
  • Clinical trial number NCT02120781 for "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia" at ClinicalTrials.gov


 

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

 

This medical treatment–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Azficel-T&oldid=1232898151"